Between 25% and 31% of patients who receive tacrolimus are reported to
experience some form of neurotoxic adverse events.
- TRADE NAMES: Envarsus XR (Veloxis); FK506; Prograf (Astellas); Protopic (Astellas)
- INDICATIONS: Prophylaxis of organ rejection, atopic dermatitis (topical)
- CLASS: Calcineurin inhibitor, Immunosuppressant, Macrolactam
- HALF-LIFE: ~8.7 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Afatinib, Alefacept, Amiodarone, Amprenavir, Atazanavir, Azacitidine, Beta blockers, Betamethasone, Boceprevir, Bosentan, Cabazitaxel, Caspofungin, Ceritinib, Cinacalcet, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Crizotinib, Cyclosporine, CYP3A4 inhibitors and inducers, Dabigatran, Dairy products, Danazol, Darunavir, Dasatinib, Delavirdine, Denileukin, Dexlansoprazole, Diclofenac, Docetaxel, Dronedarone, Efavirenz, Elbasvir & Grazoprevir, Eluxadoline, Enzalutamide, Erythromycin, Etoricoxib, Fingolimod, Gefitinib, Grapefruit Juice, Hemophilus B Vaccine, HMG-CoA reductase inhibitors, Ibuprofen, Immunosuppressants, Indinavir, Irbesartan, Itraconazole, Ketoconazole, Leflunomide, Lenalidomide, Letermovir, Lopinavir, Lovastatin, Meloxicam, Mifepristone, Mycophenolate, Nelfinavir, Nifedipine, Olmesartan, Omeprazole, Oxaliplatin, Pazopanib, Pemetrexed, Posaconazole, Potassium, Potassium-sparing diuretics, Pralatrexate, Ribociclib, Rifabutin, Rifampin, Rifapentine, Sevelamer, Simvastatin, Sirolimus, St John's Wort, Telaprevir, Telithromycin, Temsirolimus, Tinidazole, Tipranavir, Tofacitinib, Triamcinolone, Vaccines, Viloxazine, Voriconazole
- See adverse reactions attributed to class:
MALIGNANCIES AND SERIOUS INFECTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of new formulations of tacrolimus in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/11/2025
